First pharmacokinetic data of bictegravir in pregnant women living with HIV

doi:10.1097/QAD.0000000000003032

. 2021 Nov 15;35(14):2405-2406.

doi: 10.1097/QAD.0000000000003032.

First pharmacokinetic data of bictegravir in pregnant women living with HIV

Vera E Bukkems¹, Carmen Hidalgo-Tenorio², Coral Garcia², Astrid G W van Hulzen³, Olivier Richel⁴, David M Burger¹, Angela P Colbers¹, Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) network

Affiliations

¹ Department of Pharmacy, Radboud Institute for Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, the Netherlands.
² Hospital Universitario Virgen de las Nieves, Granada, Spain.
³ Department of Internal Medicine, Isala Hospital, Zwolle.
⁴ Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.

PMID: 34723856
DOI: 10.1097/QAD.0000000000003032

First pharmacokinetic data of bictegravir in pregnant women living with HIV

Vera E Bukkems et al. AIDS. 2021.

. 2021 Nov 15;35(14):2405-2406.

doi: 10.1097/QAD.0000000000003032.

Authors

Affiliations

¹ Department of Pharmacy, Radboud Institute for Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, the Netherlands.
² Hospital Universitario Virgen de las Nieves, Granada, Spain.
³ Department of Internal Medicine, Isala Hospital, Zwolle.
⁴ Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.

PMID: 34723856
DOI: 10.1097/QAD.0000000000003032

No abstract available

Similar articles

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E. Sax PE, et al. Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15. Lancet HIV. 2017. PMID: 28219610 Clinical Trial.
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, SenGupta D, Cheng A, Quirk E. Sax PE, et al. Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867499 Clinical Trial.
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Gallant J, et al. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867497 Clinical Trial.
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Orkin C, et al. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. Lancet HIV. 2020. PMID: 32504574 Clinical Trial.
Bictegravir: First Global Approval.
Markham A. Markham A. Drugs. 2018 Apr;78(5):601-606. doi: 10.1007/s40265-018-0896-4. Drugs. 2018. PMID: 29564777 Review.

See all similar articles

References

1. EACS. The European Guidelines for the treatment of HIV-positive adults in Europe: version 10.1 2020 [cited 14 April 2021]. Available at: https://www.eacsociety.org/files/guidelines-10.1_30032021_1.pdf. [Accessed 14 April 2021]
1. Pham HT, Mesplède T. Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications. Expert Opin Pharmacother 2019; 20:385–397.
1. DHHS. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States 2020 [updated 10 February 2021; cited 14 April 2021]. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Pe.... [Accessed 14 April 2021]
1. Nissim O, Lazenby GB. The use of integrase strand transfer inhibitors to treat HIV in pregnancy. J Midwifery Womens Health 2021; 66:403–406.
1. Koren G, Pariente G. Pregnancy-associated changes in pharmacokinetics and their clinical implications. Pharm Res 2018; 35:61.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- Genetic Alliance
- MedlinePlus Health Information

[1] EACS. The European Guidelines for the treatment of HIV-positive adults in Europe: version 10.1 2020 [cited 14 April 2021]. Available at: https://www.eacsociety.org/files/guidelines-10.1_30032021_1.pdf. [Accessed 14 April 2021]

[2] EACS. The European Guidelines for the treatment of HIV-positive adults in Europe: version 10.1 2020 [cited 14 April 2021]. Available at: https://www.eacsociety.org/files/guidelines-10.1_30032021_1.pdf. [Accessed 14 April 2021]

[3] Pham HT, Mesplède T. Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications. Expert Opin Pharmacother 2019; 20:385–397.

[4] Pham HT, Mesplède T. Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications. Expert Opin Pharmacother 2019; 20:385–397.

[5] DHHS. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States 2020 [updated 10 February 2021; cited 14 April 2021]. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Pe.... [Accessed 14 April 2021]

[6] DHHS. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States 2020 [updated 10 February 2021; cited 14 April 2021]. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Pe.... [Accessed 14 April 2021]

[7] Nissim O, Lazenby GB. The use of integrase strand transfer inhibitors to treat HIV in pregnancy. J Midwifery Womens Health 2021; 66:403–406.

[8] Nissim O, Lazenby GB. The use of integrase strand transfer inhibitors to treat HIV in pregnancy. J Midwifery Womens Health 2021; 66:403–406.

[9] Koren G, Pariente G. Pregnancy-associated changes in pharmacokinetics and their clinical implications. Pharm Res 2018; 35:61.

[10] Koren G, Pariente G. Pregnancy-associated changes in pharmacokinetics and their clinical implications. Pharm Res 2018; 35:61.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

First pharmacokinetic data of bictegravir in pregnant women living with HIV

Affiliations

First pharmacokinetic data of bictegravir in pregnant women living with HIV

Authors

Affiliations

Similar articles

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Similar articles

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical